XNASBNOX
Market cap2mUSD
Dec 23, Last price
0.26USD
1D
7.16%
1Q
-59.95%
Name
Bionomics Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-54.66%
Rev. gr., 5y
-64.21%
Revenues
0k
-100.00%
Net income
-15.49b
L+48,541.02%
CFO
-15m
L+3.27%
Earnings
Mar 13, 2025
Profile
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||||
Revenues | 20 -92.31% | 260 | |||||||||
Cost of revenue | 17,892,810 | 38,572 | 32,335 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (17,892,810) | (38,552) | (32,075) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | (87,320) | (210) | (190) | ||||||||
Tax Rate | |||||||||||
NOPAT | (17,805,490) | (38,342) | (31,885) | ||||||||
Net income | (15,492,166) | (31,850) 46.37% | (21,760) 150.11% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 10,112 | 3,858 | 19,703 | ||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | 155 | 114 | 110 | ||||||||
Long-term debt | 357 | 481 | 901 | ||||||||
Deferred revenue | (362) | (534) | |||||||||
Other long-term liabilities | 5,248 | 2,472 | 2,230 | ||||||||
Net debt | (12,148) | (11,640) | (22,245) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (14,681) | (14,216) | (15,020) | ||||||||
CAPEX | |||||||||||
Cash from investing activities | 319 | 429 | |||||||||
Cash from financing activities | 15,109 | 3,701 | 18,638 | ||||||||
FCF | (17,805,302) | 3,617 | (34,390) | (35,003) | |||||||
| Balance | |||||||||||
Cash | 12,608 | 12,155 | 23,174 | ||||||||
Long term investments | 53 | 79 | 82 | ||||||||
Excess cash | 12,661 | 12,235 | 23,243 | ||||||||
Stockholders' equity | (179,990) | 22,072 | 39,259 | ||||||||
Invested Capital | 203,001 | 12,767 | 18,224 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 9,987 | 1,468,620 | 1,353,240 | ||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | (17,892,147) | 771 | (38,552) | (31,309) | |||||||
EV/EBITDA | |||||||||||
Interest | 20 | 30 | |||||||||
Interest/NOPBT | |||||||||||